Who are Detemir insulin, Aspart insulin, Metformin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/detemir-insulin-aspart-insulin-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Detemir insulin, Aspart insulin, Metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detemir insulin, Aspart insulin, Metformin (Detemir insulin, Aspart insulin, Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination with biguanide. Area: Endocrinology / Diabetes.

marketed Insulin combination with biguanide Insulin receptor (detemir and aspart); AMPK and mitochondrial glycerophosphate dehydrogenase (metformin) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Detemir insulin, Aspart insulin, Metformin (Detemir insulin, Aspart insulin, Metformin) — University Hospital, Toulouse. This combination therapy uses two insulin types (long-acting detemir and rapid-acting aspart) plus metformin to lower blood glucose by increasing insulin signaling and reducing hepatic glucose production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Detemir insulin, Aspart insulin, Metformin TARGET	Detemir insulin, Aspart insulin, Metformin	University Hospital, Toulouse	marketed	Insulin combination with biguanide	Insulin receptor (detemir and aspart); AMPK and mitochondrial glycerophosphate dehydrogenase (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination with biguanide class)

University Hospital, Toulouse · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Detemir insulin, Aspart insulin, Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/detemir-insulin-aspart-insulin-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab